Tolvaptan is a non-peptide aquaretic agent that functions as a selective, competitive vasopressin receptor 2 (v2) antagonist. Aquaretic agents are being studied for water-retaining disorders like congestive heart failure and live cirrhosis.
Tolvaptan has been shown to inhibit the development of polycystic kidney disease in several animal models.